Valeant Pharmaceuticals International (VRX) Shares are Up 7.27%

Valeant Pharmaceuticals International (VRX) : Traders are bullish on Valeant Pharmaceuticals International (VRX) as it has outperformed the S&P 500 by a wide margin of 38.54% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.98%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.27% in the last 1 week, and is up 38.25% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 17.79% and the fifty day Moving Average is 29.45%. Valeant Pharmaceuticals International, Inc. is up 8.48% in the last three month period. Year-to-Date the stock performance stands at -69.67%.

Valeant Pharmaceuticals International (VRX) : Currently there are 11 street experts covering Valeant Pharmaceuticals International (VRX) stock. The most bullish and bearish price target for the stock is $81 and $22 respectively for the short term. The average price target of all the analysts comes to $42. The estimated standard deviation from the target is $15.8.


Valeant Pharmaceuticals International (NYSE:VRX): On Fridays trading session , Opening price of the stock was $31.48 with an intraday high of $31.839. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $30.52. However, the stock managed to close at $30.83, a loss of 0.84% for the day. On the previous day, the stock had closed at $31.09. The total traded volume of the day was 23,714,589 shares.

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.